PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
Nuvion Antibody Led to a Sustained Response and Remission in Follow-up to Phase 1 and Phase 1/2 studies and Was Adequately Tolerated in Patients with IV Steroid-Refractory Ulcerative Colitis FREMONT, Calif., May 22, 2007 /PRNewswire-FirstCall/ -- Data presented at the Digestive Disease Week (DDW) ...PDL BioPharma Advances Nuvion(R) Into Second Pivotal Study In ...
PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the company will advance its Nuvion(R) (visilizumab) antibody in patients with intravenous steroid ...Hutch researchers present preliminary results with antibody to treat ...
Early testing of Nuvion has indicated that the antibody is well tolerated and ... These results predict that Nuvion might be able to induce a state of ...CCFA.org: Nuvion(R) Into Second Study In Intravenous Steroid-Refractory ...
PDL BioPharma Advances Nuvion® Into Second Pivotal Study In Intravenous Steroid ... ongoing phase 2/3 clinical trial of the Nuvion antibody in patients with IVSR-UC. ...PDL BioPharma Shares May Fall on Sell-off of Products, Job Cuts ...
PDL BioPharma Inc., the developer of technology for cancer medicines, may fall in Nasdaq trading after it announced plans ... negative that Nuvion is lost, ...